<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>COPD - Clinical Study Note</title>
    <link rel="icon" type="image/png" sizes="48x48" href="/icons/favicon-48.png?v=20260301-logoexact1" />
    <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32.png?v=20260301-logoexact1" />
    <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16.png?v=20260301-logoexact1" />
    <link rel="apple-touch-icon" sizes="180x180" href="/icons/favicon-180.png?v=20260301-logoexact1" />
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #132841;
        --muted: #556c84;
        --line: #d7e4f0;
        --brand: #8a5a0f;
        --soft: #fff6e8;
        --good-soft: #eefaf6;
        --warn-soft: #fff7e8;
        --alert-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 86% 9%, #ffe9c9 0%, transparent 32%),
          radial-gradient(circle at 8% 20%, #eaf4ff 0%, transparent 24%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #36506c;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #fff8ee;
        color: #8a5a0f;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(160deg, #ffffff 0%, #fff8ee 56%, #eef7ff 100%);
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--soft);
        color: #8a5a0f;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #7a4f0d;
        font-size: clamp(1.42rem, 2.4vw, 2.04rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-grid {
        margin-top: 14px;
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #f0dfbd;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #7c6a48;
        margin-bottom: 6px;
        text-transform: uppercase;
      }

      .metric .v {
        font-size: 14px;
        color: #7a4f0d;
        font-weight: 700;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #7a4f0d;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #fff8ee;
        color: #7a4f0d;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--good-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--alert-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #7a4f0d;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram p {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .diagram svg {
        width: 100%;
        height: auto;
        display: block;
      }

      details.quiz {
        border: 1px solid var(--line);
        border-radius: 12px;
        background: #fff;
        padding: 10px 12px;
      }

      details.quiz summary {
        cursor: pointer;
        color: #1f4061;
        font-weight: 700;
      }

      details.quiz p {
        margin: 10px 0 0;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .hero-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#what-is-copd">1. Definition</a>
        <a href="#pathophysiology">2. Pathophysiology</a>
        <a href="#gold-classification">3. GOLD Classification</a>
        <a href="#rescue-bronchodilators">4. Rescue Bronchodilators</a>
        <a href="#lama">5. LAMA</a>
        <a href="#laba">6. LABA</a>
        <a href="#laba-lama">7. LABA + LAMA</a>
        <a href="#ics">8. ICS Role</a>
        <a href="#triple-therapy">9. Triple Therapy</a>
        <a href="#roflumilast">10. PDE-4 Inhibitor</a>
        <a href="#acute-exacerbation">11. Acute Exacerbation</a>
        <a href="#oxygen-therapy">12. Oxygen Therapy</a>
        <a href="#management-recap-drill">Management Recap Drill</a>
        <a href="#guidelines">Guidelines</a>
        <a href="#exam-traps">13. Common Exam Traps</a>
        <a href="#quick-revision">14. Quick Revision Summary</a>
        <a href="#practice-questions">Practice Questions</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Respiratory Disorders</span>
          <h1>COPD</h1>
          <p class="subtitle">
            Clinical overview and exam mastery guide for GOLD treatment groups,
            maintenance inhaler logic, exacerbation management, and oxygen criteria.
          </p>
          <div class="hero-grid">
            <div class="metric">
              <div class="k">Core Disease</div>
              <div class="v">Progressive airflow limitation</div>
            </div>
            <div class="metric">
              <div class="k">Major Cause</div>
              <div class="v">Smoking exposure</div>
            </div>
            <div class="metric">
              <div class="k">Maintenance Base</div>
              <div class="v">LAMA and/or LABA</div>
            </div>
            <div class="metric">
              <div class="k">Oxygen Target</div>
              <div class="v">SpO2 88-92%</div>
            </div>
          </div>
          <div class="diagram">
            <p>COPD Structural Disease Model</p>
            <svg viewBox="0 0 760 220" role="img" aria-label="COPD pathophysiology illustration">
              <rect x="0" y="0" width="760" height="220" rx="12" fill="#fbfdff" />
              <rect x="20" y="25" width="220" height="70" rx="10" fill="#fff8ee" stroke="#f0dfbd" />
              <text x="130" y="48" text-anchor="middle" font-size="13" fill="#7a4f0d" font-weight="700">Chronic irritation</text>
              <text x="130" y="66" text-anchor="middle" font-size="12" fill="#7c6a48">smoke / biomass / pollutants</text>
              <rect x="270" y="25" width="220" height="70" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
              <text x="380" y="48" text-anchor="middle" font-size="13" fill="#1f4467" font-weight="700">Airway disease</text>
              <text x="380" y="66" text-anchor="middle" font-size="12" fill="#5f7488">mucus + narrowing</text>
              <rect x="520" y="25" width="220" height="70" rx="10" fill="#fff0f0" stroke="#f2cbcb" />
              <text x="630" y="48" text-anchor="middle" font-size="13" fill="#8a3a3a" font-weight="700">Parenchymal loss</text>
              <text x="630" y="66" text-anchor="middle" font-size="12" fill="#8a4e4e">emphysema + recoil loss</text>
              <path d="M240 60 L270 60" stroke="#9cb3c7" stroke-width="3" />
              <path d="M490 60 L520 60" stroke="#9cb3c7" stroke-width="3" />
              <rect x="20" y="120" width="720" height="75" rx="10" fill="#ffffff" stroke="#d8e4f2" />
              <text x="380" y="147" text-anchor="middle" font-size="13" fill="#2a4963" font-weight="700">Result: persistent airflow obstruction (not fully reversible)</text>
              <text x="380" y="166" text-anchor="middle" font-size="12" fill="#45637e">Therapy focus: bronchodilation + exacerbation prevention + smoking cessation</text>
            </svg>
          </div>
        </header>

        <section class="section" id="what-is-copd">
          <h2>1. Definition</h2>
          <p>
            COPD is a progressive, largely irreversible airflow limitation syndrome
            driven by chronic bronchitis, emphysema, or both. Smoking is the main cause.
          </p>
          <div class="chips">
            <span class="chip">Chronic bronchitis</span>
            <span class="chip">Emphysema</span>
            <span class="chip">Not fully reversible</span>
          </div>
        </section>

        <section class="section" id="pathophysiology">
          <h2>2. Pathophysiology</h2>
          <div class="flow">
            <div class="step"><strong>Step 1:</strong> Chronic airway inflammation develops.</div>
            <div class="arrow">&#8595;</div>
            <div class="step"><strong>Step 2:</strong> Airway narrowing and mucus hypersecretion increase resistance.</div>
            <div class="arrow">&#8595;</div>
            <div class="step"><strong>Step 3:</strong> Alveolar wall destruction causes air trapping and reduced recoil.</div>
          </div>
          <div class="callout alert">Unlike asthma, airflow obstruction in COPD is not fully reversible.</div>
        </section>

        <section class="section" id="gold-classification">
          <h2>3. GOLD Classification (Treatment-Based)</h2>
          <p>Classify by symptom burden (mMRC/CAT) and exacerbation history.</p>
          <div class="chips">
            <span class="chip">Group A</span>
            <span class="chip">Group B</span>
            <span class="chip">Group E</span>
          </div>
          <div class="diagram">
            <p>GOLD Grouping and Initial Treatment</p>
            <svg viewBox="0 0 760 190" role="img" aria-label="GOLD A B E treatment overview">
              <rect x="0" y="0" width="760" height="190" rx="12" fill="#fbfdff" />
              <rect x="30" y="48" width="220" height="95" rx="10" fill="#fff8ee" stroke="#f0dfbd" />
              <text x="140" y="72" text-anchor="middle" font-size="14" fill="#7a4f0d" font-weight="700">Group A</text>
              <text x="140" y="94" text-anchor="middle" font-size="12" fill="#7c6a48">Low symptoms / low exacerbation risk</text>
              <text x="140" y="113" text-anchor="middle" font-size="12" fill="#7a4f0d">Single bronchodilator</text>
              <rect x="270" y="48" width="220" height="95" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
              <text x="380" y="72" text-anchor="middle" font-size="14" fill="#1f4467" font-weight="700">Group B</text>
              <text x="380" y="94" text-anchor="middle" font-size="12" fill="#5f7488">More symptoms / lower exacerbation risk</text>
              <text x="380" y="113" text-anchor="middle" font-size="12" fill="#1f4467">LABA or LAMA</text>
              <rect x="510" y="48" width="220" height="95" rx="10" fill="#fff0f0" stroke="#f2cbcb" />
              <text x="620" y="72" text-anchor="middle" font-size="14" fill="#8a3a3a" font-weight="700">Group E</text>
              <text x="620" y="94" text-anchor="middle" font-size="12" fill="#8a4e4e">Exacerbation-prone</text>
              <text x="620" y="113" text-anchor="middle" font-size="12" fill="#8a3a3a">LABA + LAMA (consider ICS)</text>
            </svg>
          </div>
        </section>

        <section class="section" id="rescue-bronchodilators">
          <h2>4. Short-Acting Bronchodilators (Rescue)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Albuterol (SABA)</h3>
              <ul>
                <li>Dose: 2 puffs every 4 to 6 hours as needed or 2.5 mg neb as needed</li>
                <li>MOA: beta-2 agonist bronchodilation</li>
              </ul>
            </div>
            <div class="box">
              <h3>Ipratropium (SAMA)</h3>
              <ul>
                <li>Dose: 2 puffs (17 mcg per puff) four times daily</li>
                <li>MOA: muscarinic blockade to reduce bronchoconstriction</li>
                <li>Side effect: dry mouth</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="lama">
          <h2>5. Long-Acting Muscarinic Antagonists (LAMA)</h2>
          <div class="box">
            <h3>Tiotropium (first-line maintenance)</h3>
            <ul>
              <li>MOA: M3 receptor blockade with long-acting bronchodilation</li>
              <li>Dose: 18 mcg inhaled once daily (HandiHaler) or 2.5 mcg (2 inhalations) daily (Respimat)</li>
              <li>Side effects: dry mouth, urinary retention</li>
              <li>Caution: narrow-angle glaucoma</li>
            </ul>
          </div>
        </section>

        <section class="section" id="laba">
          <h2>6. LABA (Long-Acting Beta Agonists)</h2>
          <div class="box">
            <ul>
              <li>Salmeterol dose: 50 mcg twice daily</li>
              <li>MOA: sustained bronchodilation</li>
              <li>Maintenance use is appropriate in COPD</li>
            </ul>
          </div>
          <div class="callout warn">High-yield distinction: LABA can be used alone in COPD (unlike asthma).</div>
        </section>

        <section class="section" id="laba-lama">
          <h2>7. LABA + LAMA Combination</h2>
          <div class="box">
            <ul>
              <li>Preferred in moderate to severe symptomatic COPD</li>
              <li>Example: umeclidinium/vilanterol, 1 inhalation once daily</li>
            </ul>
          </div>
        </section>

        <section class="section" id="ics">
          <h2>8. Inhaled Corticosteroids (ICS) Role</h2>
          <div class="box">
            <ul>
              <li>Use in frequent exacerbations and/or high eosinophils</li>
              <li>Example (in combination): fluticasone 250 to 500 mcg twice daily</li>
              <li>Risk: increased pneumonia incidence</li>
              <li>Not first-line as monotherapy in COPD</li>
            </ul>
          </div>
        </section>

        <section class="section" id="triple-therapy">
          <h2>9. Triple Therapy (ICS + LABA + LAMA)</h2>
          <div class="box">
            <ul>
              <li>For severe disease or frequent exacerbations</li>
              <li>Example: fluticasone/umeclidinium/vilanterol, 1 inhalation once daily</li>
            </ul>
          </div>
        </section>

        <section class="section" id="roflumilast">
          <h2>10. Phosphodiesterase-4 Inhibitor</h2>
          <div class="box">
            <h3>Roflumilast</h3>
            <ul>
              <li>Use: severe COPD with chronic bronchitis and frequent exacerbations</li>
              <li>MOA: PDE-4 inhibition reduces inflammation</li>
              <li>Dose: 500 mcg orally once daily</li>
              <li>Side effects: weight loss, diarrhea, insomnia</li>
              <li>Contraindication: moderate to severe liver impairment</li>
            </ul>
          </div>
        </section>

        <section class="section" id="acute-exacerbation">
          <h2>11. Acute COPD Exacerbation</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Bronchodilator + Steroid Core</h3>
              <ul>
                <li>Frequent SABA plus or minus SAMA dosing</li>
                <li>Prednisone 40 mg orally daily for 5 days</li>
              </ul>
            </div>
            <div class="box">
              <h3>Antibiotic Trigger Criteria</h3>
              <ul>
                <li>Increased sputum purulence</li>
                <li>Increased sputum volume</li>
                <li>Increased dyspnea</li>
              </ul>
            </div>
          </div>
          <div class="box stack">
            <h3>Common 5-7 day regimens if infection suspected</h3>
            <div class="chips">
              <span class="chip">Amoxicillin/clavulanate</span>
              <span class="chip">Azithromycin</span>
              <span class="chip">Doxycycline</span>
            </div>
          </div>
        </section>

        <section class="section" id="oxygen-therapy">
          <h2>12. Oxygen Therapy</h2>
          <div class="box">
            <ul>
              <li>Indicated when PaO2 <= 55 mmHg or oxygen saturation <= 88%</li>
              <li>Long-term oxygen therapy improves survival in qualifying patients</li>
              <li>Target saturation: 88-92%</li>
              <li>Avoid over-oxygenation due to CO2 retention risk</li>
            </ul>
          </div>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step"><strong>Group A:</strong> single bronchodilator.</div>
            <div class="arrow">&#8595;</div>
            <div class="step"><strong>Group B:</strong> LABA or LAMA.</div>
            <div class="arrow">&#8595;</div>
            <div class="step"><strong>Group E:</strong> LABA + LAMA, then consider ICS for frequent exacerbations.</div>
            <div class="arrow">&#8595;</div>
            <div class="step"><strong>Exacerbation:</strong> SABA + steroid plus or minus antibiotics.</div>
          </div>
        </section>

        <section class="section refs" id="guidelines">
          <h2>Guideline References (Management)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>GOLD Guidelines</h3>
              <a href="https://goldcopd.org" target="_blank" rel="noopener">https://goldcopd.org</a>
            </div>
            <div class="box">
              <h3>Guideline Scope</h3>
              <ul>
                <li>Group A/B/E classification</li>
                <li>Inhaler selection and escalation</li>
                <li>Exacerbation and oxygen criteria</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>13. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">LABA monotherapy is allowed in COPD (unlike asthma).</div>
            <div class="callout alert">ICS can increase pneumonia risk in COPD.</div>
            <div class="callout alert">A 5-day prednisone course is usually sufficient in exacerbation.</div>
            <div class="callout alert">Oxygen target is 88-92%, not normal-range saturation.</div>
            <div class="callout alert">LAMA is a strong first-line maintenance option.</div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>14. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Must Remember</h3>
              <ul>
                <li>Smoking is the major COPD cause</li>
                <li>LAMA or LABA is baseline maintenance</li>
                <li>LABA/LAMA combination is preferred in symptomatic disease</li>
                <li>Add ICS for frequent exacerbators or high eosinophils</li>
                <li>Exacerbation core: bronchodilator + steroid</li>
              </ul>
            </div>
            <div class="box">
              <h3>High-Yield Subtopics</h3>
              <ul>
                <li>GOLD A/B/E treatment logic</li>
                <li>LAMA/LABA dosing and role</li>
                <li>ICS limitations in COPD</li>
                <li>Oxygen criteria and target range</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="practice-questions">
          <h2>Practice Questions</h2>
          <div class="stack">
            <details class="quiz">
              <summary>1) Which maintenance class is a strong first-line option in COPD?</summary>
              <p><strong>Answer:</strong> LAMA (for example, tiotropium).</p>
            </details>
            <details class="quiz">
              <summary>2) Is LABA monotherapy acceptable in COPD?</summary>
              <p><strong>Answer:</strong> Yes. Unlike asthma, LABA alone can be used in COPD maintenance.</p>
            </details>
            <details class="quiz">
              <summary>3) Typical systemic steroid duration in acute COPD exacerbation?</summary>
              <p><strong>Answer:</strong> Prednisone 40 mg daily for 5 days.</p>
            </details>
            <details class="quiz">
              <summary>4) When should long-term oxygen be considered?</summary>
              <p><strong>Answer:</strong> PaO2 <= 55 mmHg or oxygen saturation <= 88%.</p>
            </details>
            <details class="quiz">
              <summary>5) What oxygen saturation target is usually used in COPD exacerbation?</summary>
              <p><strong>Answer:</strong> 88-92% to avoid over-oxygenation and CO2 retention.</p>
            </details>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
